EyePoint Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Good afternoon, everyone, and thanks for joining us for the EyePoint session. As you know, EyePoint is an implant technology developing TKIs for DME and hopefully maybe one day wet AMD. With us today are Jay Duker, the CEO of EyePoint, and George Elston, CFO. Thank you for joining us, and maybe you can sort of just level set us and tell us where EyePoint stands today after Sure an unfortunate outcome for LUGANO and LUCIA.
Yeah. Thank you very much, Annabel, for having us, and thanks for the opportunity. So, quite simply, where we stand today is we're a DME company. Diabetic macular edema is currently a $5 billion market worldwide, with $3 billion in the U.S. We are currently in two identical simultaneous phase III trials in DME, COMO and CAPRI, that are both fully enrolled, and we should see the top line data in just under a year, at the beginning of Q4 of next year. We have a lot of reasons to be optimistic about the DME results, despite, as you know, our primary endpoint miss in wet AMD, and happy to expound and go into detail about those this afternoon.
Mm-hmm. Okay, sure. Why don't we go Well, before we get into that, maybe you can speak to how we should think about TKIs for retinal conditions, and is it something Does this tell us more about TKIs in general, or is it something specific to DURAVYU? Is it something specific to clinical trial design? Maybe you can expound on that a little bit.
That's a great question, and I'm not sure we can answer the question now or try to extrapolate about TKIs in general. What we know about our TKI is that it's quite active pre-clinically. Based on the PK data that we have in the phase III trials, we know that the inserts were releasing at levels that we can extrapolate were many times above IC50 in the retina and choroid. What we also know by the PK data systemically is, of course, we redosed at month eight during the wet AMD trials, and we actually saw higher levels of the drug, vorolanib, after the redosing. Yet it's hard to look at the clinical data and see that there was any difference in outcome after the second injection. If someone suggested that perhaps the higher dose might have worked, we don't see any evidence of that.
TKIs in preclinical models work quite well. In fact, there's a model that we ran of the chick chorioallantoic membrane model where our TKIs and others at IC50 worked better than a ligand blocker did in this model of neovascularization. The science is there. The drug was releasing. The drug was there in doses that should be effective. Again, I think that if you look at the primary endpoint, we believe that the evidence is clear that the drug was active. In both trials, we showed a gain of over two letters, and that shows activity. Certainly, if you look at the subgroup of patients who were supplement-free after the load, in both trials, over 50% of the eyes went the rest of the trial up to week 56 with no additional treatment, just our drug.
In the pooled analysis, those eyes were non-inferior to the unsupplemented EYLEA eyes. We know, and at least you could argue, if the lack of supplement shows the activity in those eyes, those eyes did great.
The question is that a large subgroup of patients that we can identify a priori, and therefore, if we were to run or someone was to run a third trial in wet AMD, would we be able, through inclusion and exclusion criteria, to identify that group of patients and have a more positive result? The other thing from both trials to note is the secondary endpoints.
We did quite well in the secondary endpoints. In particular, the one that really matters the most besides visual acuity is safety. We dosed the drug in over 440 patients for one year with redosing, and the safety looks really quite strong. When you look at the AE tables, the mismatch, none of the safety concerns were more than 8%, and most were around 2% or 3%. Any of the mismatch you saw was a mismatch for active wet AMD, meaning AEs that involved retinal hemorrhage or fluid were slightly greater in our arms than in the control arm because we had more eyes that had active wet AMD by definition, because we had about 30% more supplements in our arm than in the control arm. So, the safety really looks fine.
The other secondary endpoint, which we think is de-risking for DME, is the OCT data, which is a measurement of fluid in the retina. The CSTs in the pooled data from the two trials in the DURAVYU arms showed a difference of only 10 microns. That's tiny. That's a standard deviation. A normal CST is up to about 325 microns. So a 10-micron difference is really not clinically important at all. So between the safety and the control of the fluid, we think both of those are really important to de-risk the DME result. Also, both trials showed the exact same reduction in treatment burden. On average, if approved in the real world, if this would hold, we would have on average of about two injections less than on-label EYLEA for wet AMD.
Once again, showing that the drug was active and potent, just wasn't able to hold the vision quite enough to be non-inferior.
Right. Does that also maybe speak to on-label EYLEA being more potent than what we understand it to be real world?
I don't know if we can say that per se. On-label EYLEA performed in our study the way one would expect, gained slightly under six letters. That, I think that that's consistent with other trials. There's always a few exceptions. Trials that enroll nowadays where the patients who have wet AMD are usually now being seen at an earlier point in their disease and enrolling in trials earlier, this is what one would expect.
Of course, in the real world, on average, patients get fewer than every other month- EYLEA, not necessarily because that's what the doctor wants to give.
There's real-world issues around patients coming in. That's again why sustained release makes a lot of sense. Because if there are missed visits or patients just can't come in for visits, or the treatment burden after years becomes too much, if you have an insert that releases for six months or longer with a single injection, that obviously can take care of those patients. Of course, 40% of wet AMD patients drop out from treatment after a year and a half, which is an amazingly high number. Many of those probably do it because they just can't keep up with the visits. Again, a sustained release offering would really make a difference to those number of patients who drop out.
Back to the question about how the EYLEA arm performed, I think it performed as expected, as one in a non-inferiority trial.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
